These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2199 related articles for article (PubMed ID: 12819933)

  • 21. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency.
    Murray CW; Carr MG; Callaghan O; Chessari G; Congreve M; Cowan S; Coyle JE; Downham R; Figueroa E; Frederickson M; Graham B; McMenamin R; O'Brien MA; Patel S; Phillips TR; Williams G; Woodhead AJ; Woolford AJ
    J Med Chem; 2010 Aug; 53(16):5942-55. PubMed ID: 20718493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular therapeutics in patients with cancer unresponsive to conventional treatments].
    Valdespino-Gómez VM; Valdespino-Castillo VE
    Gac Med Mex; 2008; 144(4):333-44. PubMed ID: 18942268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
    McDermott U; Settleman J
    J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highlights in experimental therapeutics.
    Burger AM
    Cancer Lett; 2007 Jan; 245(1-2):11-21. PubMed ID: 16647200
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP; Funk L; Meng J; Collins M; Zhou JZ; Johnson MC; Ekker A; Wang J; Mehta P; Yin MJ; Rodgers C; Davies JF; Bayman E; Smeal T; Maegley KA; Gehring MR
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6273-8. PubMed ID: 18929486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat shock protein 90: a unique chemotherapeutic target.
    Cullinan SB; Whitesell L
    Semin Oncol; 2006 Aug; 33(4):457-65. PubMed ID: 16890800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Purine-scaffold Hsp90 inhibitors.
    Chiosis G; Tao H
    IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. When will the genomics investment pay off for antibacterial discovery?
    Mills SD
    Biochem Pharmacol; 2006 Mar; 71(7):1096-102. PubMed ID: 16387281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies.
    Rowinsky EK
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4220s-4226s. PubMed ID: 15217962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic strategies for personalized cancer therapy.
    Garman KS; Nevins JR; Potti A
    Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R226-32. PubMed ID: 17911165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic biomarkers for molecular cancer therapeutics.
    Sarker D; Workman P
    Adv Cancer Res; 2007; 96():213-68. PubMed ID: 17161682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 110.